These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20564337)

  • 1. Use of enthalpy and Gibbs free energy to evaluate the risk of amorphous formation.
    Hsieh DS; Sarsfield BA; Davidovich M; DiMemmo LM; Chang SY; Kiang S
    J Pharm Sci; 2010 Sep; 99(9):4096-105. PubMed ID: 20564337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2010 Mar; 99(3):1254-64. PubMed ID: 19697391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation.
    Amharar Y; Curtin V; Gallagher KH; Healy AM
    Int J Pharm; 2014 Sep; 472(1-2):241-7. PubMed ID: 24968139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance.
    Alie J; Menegotto J; Cardon P; Duplaa H; Caron A; Lacabanne C; Bauer M
    J Pharm Sci; 2004 Jan; 93(1):218-33. PubMed ID: 14648651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico prediction of drug solubility. 3. Free energy of solvation in pure amorphous matter.
    Lüder K; Lindfors L; Westergren J; Nordholm S; Kjellander R
    J Phys Chem B; 2007 Jun; 111(25):7303-11. PubMed ID: 17550285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of melting temperature and enthalpy of drug crystals: theoretical aspects.
    Hasa D; Voinovich D; Perissutti B; Grassi G; Fiorentino S; Farra R; Abrami M; Colombo I; Grassi M
    Eur J Pharm Sci; 2013 Sep; 50(1):17-28. PubMed ID: 23567466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Amorphous Drug Stability Predictions Using Easily Calculated, Predicted, and Measured Parameters.
    Nurzyńska K; Booth J; Roberts CJ; McCabe J; Dryden I; Fischer PM
    Mol Pharm; 2015 Sep; 12(9):3389-98. PubMed ID: 26236939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of solution nonideality of a pseudomorphic drug system through a comprehensive thermodynamic framework for the design of a crystallization process.
    Nordstrom FL; Rasmuson A; Sheikh AY
    J Pharm Sci; 2004 Apr; 93(4):995-1004. PubMed ID: 14999735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the Solubility Advantage of Amorphous Pharmaceuticals: A Novel Thermodynamic Approach.
    Paus R; Ji Y; Vahle L; Sadowski G
    Mol Pharm; 2015 Aug; 12(8):2823-33. PubMed ID: 26107071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Estimation of Amorphous Solubility Enhancement Using Thermoanalytical Data: Determination of the Amorphous/Crystalline Solubility Ratio for Pure Indomethacin and Felodipine.
    Skrdla PJ; Floyd PD; Dell'orco PC
    J Pharm Sci; 2016 Sep; 105(9):2625-2630. PubMed ID: 27372548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility.
    Zhou D; Zhang GG; Law D; Grant DJ; Schmitt EA
    J Pharm Sci; 2002 Aug; 91(8):1863-72. PubMed ID: 12115813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of drug-polymer thermodynamic phase diagrams using Flory-Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions.
    Tian Y; Booth J; Meehan E; Jones DS; Li S; Andrews GP
    Mol Pharm; 2013 Jan; 10(1):236-48. PubMed ID: 23110477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermodynamics of water-solid interactions in crystalline and amorphous pharmaceutical materials.
    Sacchetti M
    J Pharm Sci; 2014 Sep; 103(9):2772-2783. PubMed ID: 24327540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuances in the Calculation of Amorphous Solubility Enhancement Ratio.
    Manchanda A; Kleppe MS; Bogner RH
    J Pharm Sci; 2019 Nov; 108(11):3560-3574. PubMed ID: 31271772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temperature and solvent effects in the solubility of some pharmaceutical compounds: Measurements and modeling.
    Mota FL; Carneiro AP; Queimada AJ; Pinho SP; Macedo EA
    Eur J Pharm Sci; 2009 Jun; 37(3-4):499-507. PubMed ID: 19406228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amorphous and Crystalline Particulates: Challenges and Perspectives in Drug Delivery.
    Al-Obaidi H; Majumder M; Bari F
    Curr Pharm Des; 2017; 23(3):350-361. PubMed ID: 27829335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
    Qian F; Huang J; Hussain MA
    J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Accuracy of Amorphous Solubility Advantage Calculation by Comparison with Experimental Solubility Measurement in Buffer and Biorelevant Media.
    Zhang W; Haser A; Hou HH; Nagapudi K
    Mol Pharm; 2018 Apr; 15(4):1714-1723. PubMed ID: 29522344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of solubility curves and melting properties of organic and pharmaceutical compounds.
    Nordström FL; Rasmuson AC
    Eur J Pharm Sci; 2009 Feb; 36(2-3):330-44. PubMed ID: 19022383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.